Generic Name: bictegravir/emtricitabine/tenofovir alafenamide
Brand Name: TBC
Manufacturer: Gilead Sciences Canada, Inc.
Indications: HIV-1 infection
Manufacturer Requested Reimbursement Criteria1:
For the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults.
Submission Type: New Combination
Project Status: Pending
Call For Patient Input: April 2, 2018
Patient Input Closed: May 22, 2018
Anticipated Date: April 30, 2018
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
infectious diseases, hiv/aids